Oct 17th 2012 - Edison Investment Research today published a report on Prima Biomed entitled "Interim CVac Data". In summary, the report says:
Interim data from the 63-patient CAN-003 Phase IIb trial of Prima’s CVac immunotherapeutic in ovarian cancer in first or second remission showed safety and some preliminary evidence of activity. However, the lack of a more definitive signal, even though this would be unlikely to be seen at this point, caused a 12% sell-off in Prima’s shares. Full data from this study, which may provide this proof of concept, are due in c 12 months’ time. However, Prima’s investment case hinges on the outcome of a larger 1,000 patient CANVAS Phase II/III study of CVac, given as first line maintenance in ovarian cancer, for which data are due in March 2015.
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »